These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

662 related items for PubMed ID: 12802023

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. A trial of 17 alpha-hydroxyprogesterone caproate to prevent prematurity in twins.
    Rouse DJ, Caritis SN, Peaceman AM, Sciscione A, Thom EA, Spong CY, Varner M, Malone F, Iams JD, Mercer BM, Thorp J, Sorokin Y, Carpenter M, Lo J, Ramin S, Harper M, Anderson G, National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network.
    N Engl J Med; 2007 Aug 02; 357(5):454-61. PubMed ID: 17671253
    [Abstract] [Full Text] [Related]

  • 3. 17-hydroxyprogesterone caproate for preterm rupture of the membranes: a multicenter, randomized, double-blind, placebo-controlled trial.
    Combs CA, Garite TJ, Maurel K, Abril D, Das A, Clewell W, Heyborne K, How H, Huang W, Lewis D, Lu G, Miller H, Nageotte M, Porreco R, Sheikh A, Tran L, Obstetrix Collaborative Research Network.
    Am J Obstet Gynecol; 2015 Sep 02; 213(3):364.e1-12. PubMed ID: 25979614
    [Abstract] [Full Text] [Related]

  • 4. Gestational age at initiation of 17-alpha hydroxyprogesterone caproate and recurrent preterm birth.
    Ning A, Vladutiu CJ, Dotters-Katz SK, Goodnight WH, Manuck TA.
    Am J Obstet Gynecol; 2017 Sep 02; 217(3):371.e1-371.e7. PubMed ID: 28526452
    [Abstract] [Full Text] [Related]

  • 5. 17α-hydroxyprogesterone caproate for the prevention of adverse neonatal outcome in multiple pregnancies: a randomized controlled trial.
    Lim AC, Schuit E, Bloemenkamp K, Bernardus RE, Duvekot JJ, Erwich JJHM, van Eyck J, Groenwold RHH, Hasaart THM, Hummel P, Kars MM, Kwee A, van Oirschot CM, van Pampus MG, Papatsonis D, Porath MM, Spaanderman ME, Willekes C, Wilpshaar J, Mol BWJ, Bruinse HW.
    Obstet Gynecol; 2011 Sep 02; 118(3):513-520. PubMed ID: 21860279
    [Abstract] [Full Text] [Related]

  • 6. Vaginal progesterone vs intramuscular 17-hydroxyprogesterone caproate for prevention of recurrent preterm birth: a randomized controlled trial.
    Boelig RC, Schoen CN, Frey H, Gimovsky AC, Springel E, Backley S, Berghella V.
    Am J Obstet Gynecol; 2022 May 02; 226(5):722.e1-722.e12. PubMed ID: 35189093
    [Abstract] [Full Text] [Related]

  • 7. Recurrent hope for the treatment of preterm delivery.
    Doggrell SA.
    Expert Opin Pharmacother; 2003 Dec 02; 4(12):2363-6. PubMed ID: 14640934
    [Abstract] [Full Text] [Related]

  • 8. 17-OHPC to Prevent Recurrent Preterm Birth in Singleton Gestations (PROLONG Study): A Multicenter, International, Randomized Double-Blind Trial.
    Blackwell SC, Gyamfi-Bannerman C, Biggio JR, Chauhan SP, Hughes BL, Louis JM, Manuck TA, Miller HS, Das AF, Saade GR, Nielsen P, Baker J, Yuzko OM, Reznichenko GI, Reznichenko NY, Pekarev O, Tatarova N, Gudeman J, Birch R, Jozwiakowski MJ, Duncan M, Williams L, Krop J.
    Am J Perinatol; 2020 Jan 02; 37(2):127-136. PubMed ID: 31652479
    [Abstract] [Full Text] [Related]

  • 9. Nonresponse to 17-alpha hydroxyprogesterone caproate for recurrent spontaneous preterm birth prevention: clinical prediction and generation of a risk scoring system.
    Manuck TA, Stoddard GJ, Fry RC, Esplin MS, Varner MW.
    Am J Obstet Gynecol; 2016 Nov 02; 215(5):622.e1-622.e8. PubMed ID: 27418444
    [Abstract] [Full Text] [Related]

  • 10. Weekly 17 alpha-hydroxyprogesterone caproate to prevent preterm birth among women living with HIV: a randomised, double-blind, placebo-controlled trial.
    Price JT, Vwalika B, Freeman BL, Cole SR, Saha PT, Mbewe FM, Phiri WM, Peterson M, Muyangwa D, Sindano N, Mwape H, Smithmyer ME, Kasaro MP, Rouse DJ, Goldenberg RL, Chomba E, Stringer JSA.
    Lancet HIV; 2021 Oct 02; 8(10):e605-e613. PubMed ID: 34509197
    [Abstract] [Full Text] [Related]

  • 11. Pregnancy duration with use of 17-α-hydroxyprogesterone caproate in a retrospective cohort at high risk of recurrent preterm birth.
    Massa K, Childress K, Vricella LK, Boerrigter A, Franklin BHK, Sauer M, Armbruster R, Tomlinson T.
    Am J Obstet Gynecol MFM; 2020 Nov 02; 2(4):100219. PubMed ID: 33345927
    [Abstract] [Full Text] [Related]

  • 12. Predictors of response to 17-alpha hydroxyprogesterone caproate for prevention of recurrent spontaneous preterm birth.
    Manuck TA, Esplin MS, Biggio J, Bukowski R, Parry S, Zhang H, Huang H, Varner MW, Andrews W, Saade G, Sadovsky Y, Reddy UM, Ilekis J, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Genomics and Proteomics Network for Preterm Birth Research (GPN-PBR).
    Am J Obstet Gynecol; 2016 Mar 02; 214(3):376.e1-8. PubMed ID: 26692181
    [Abstract] [Full Text] [Related]

  • 13. Pharmacological use of progesterone and 17-alpha-hydroxyprogesterone caproate in the prevention of preterm delivery.
    Facchinetti F, Vaccaro V.
    Minerva Ginecol; 2009 Oct 02; 61(5):401-9. PubMed ID: 19749671
    [Abstract] [Full Text] [Related]

  • 14. 17-alpha-hydroxyprogesterone caproate for maintenance tocolysis: a systematic review and metaanalysis of randomized trials.
    Saccone G, Suhag A, Berghella V.
    Am J Obstet Gynecol; 2015 Jul 02; 213(1):16-22. PubMed ID: 25659469
    [Abstract] [Full Text] [Related]

  • 15. Vaginal progesterone compared with intramuscular 17-alpha-hydroxyprogesterone caproate for prevention of recurrent preterm birth in singleton gestations: a systematic review and meta-analysis.
    Boelig RC, Locci M, Saccone G, Gragnano E, Berghella V.
    Am J Obstet Gynecol MFM; 2022 Sep 02; 4(5):100658. PubMed ID: 35562009
    [Abstract] [Full Text] [Related]

  • 16. Placental histology for targeted risk assessment of recurrent spontaneous preterm birth.
    Suresh S, Freedman A, Adams M, Hirsch E, Ernst LM.
    Am J Obstet Gynecol; 2024 Apr 02; 230(4):452.e1-452.e11. PubMed ID: 37751829
    [Abstract] [Full Text] [Related]

  • 17. Gestational age at initiation of 17-hydroxyprogesterone caproate (17P) and recurrent preterm delivery.
    González-Quintero VH, Istwan NB, Rhea DJ, Smarkusky L, Hoffman MC, Stanziano GJ.
    J Matern Fetal Neonatal Med; 2007 Mar 02; 20(3):249-52. PubMed ID: 17437227
    [Abstract] [Full Text] [Related]

  • 18. Prevention of preterm delivery after successful tocolysis in preterm labor by 17 alpha-hydroxyprogesterone caproate: a randomized controlled trial.
    Rozenberg P, Chauveaud A, Deruelle P, Capelle M, Winer N, Desbrière R, Perrotin F, Bohec C, Connan L, Vayssière C, Langer B, Mantel A, Azimi S, Porcher R, Azria E, Groupe De Recherche En Obstétrique et Gynécologie.
    Am J Obstet Gynecol; 2012 Mar 02; 206(3):206.e1-9. PubMed ID: 22381603
    [Abstract] [Full Text] [Related]

  • 19. Outcomes With Cerclage Alone Compared With Cerclage Plus 17α-Hydroxyprogesterone Caproate.
    Stetson B, Hibbard JU, Wilkins I, Leftwich H.
    Obstet Gynecol; 2016 Nov 02; 128(5):983-988. PubMed ID: 27741201
    [Abstract] [Full Text] [Related]

  • 20. A randomised controlled double-blind clinical trial of 17-hydroxyprogesterone caproate for the prevention of preterm birth in twin gestation (PROGESTWIN): evidence for reduced neonatal morbidity.
    Awwad J, Usta IM, Ghazeeri G, Yacoub N, Succar J, Hayek S, Saasouh W, Nassar AH.
    BJOG; 2015 Jan 02; 122(1):71-9. PubMed ID: 25163819
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 34.